Key Takeaways
Treat a genome edit as a choice about descendants, not just a patient.
Two kinds of edit. Somatic editing changes body cells in an existing person. Those changes are not inherited. Germline editing changes eggs, sperm, or early embryos, and becomes heritable if the embryo is used to start a pregnancy. It does not simply treat a patient. It changes what a family line may pass on. The distinction matters even when the intended edit is identical.
The family behind the debate. Huntington's disease often gives each child of an affected parent a 50 percent chance of inheriting the faulty gene. Jane Mervar, whose husband and three daughters developed the disease, described CRISPR as a hope for her family. That hope is understandable, but a possible future treatment for a patient and an intervention that shapes descendants raise different questions.
The distinction resembles the difference between repairing harm for someone who can choose and making an irreversible decision for people not yet born. That does not make heritable editing automatically wrong, but it changes who must be considered: the future child, descendants, and communities affected by the choice. The family stories give this debate its moral force, while also making it easy to let compassion for a particular family settle a public question prematurely. Compassion should motivate careful inquiry, not substitute for it.
CRISPR cuts DNA, but cellular repair makes the result less programmable.
A guided cut. CRISPR uses a guide RNA to direct the Cas9 enzyme to a matching DNA sequence. Cas9 cuts both strands, and the cell repairs the break. Researchers can use that repair process to disrupt a gene or, with a supplied DNA template, attempt a more precise correction. The tool is often compared to molecular scissors, but the cell, not the researcher, performs the repair.
Errors are consequential. Off-target effects are unintended changes elsewhere in the genome. Even an edit made at the intended location can have harmful on-target effects, while one gene change may affect other genes or tissues. In embryos, mosaicism means some cells are edited and others are not. These uncertainties matter because harmful changes could cause disease, cancer, or effects that appear only years later.
The scissors metaphor is memorable, but it can make editing sound more controlled than it is. A cut does not dictate how a living cell will mend itself. This is a useful general lesson about biological interventions: precision at the point of entry does not guarantee predictable effects across a system. The relevant standard is not whether a tool can reach a target, but whether its results can be measured reliably, including rare or delayed harms. Uncertainty does not prove that research must stop, but it does make claims of easy control premature.
Before calling germline editing necessary, compare safer routes to family-making.
Alternatives matter. Couples at risk of passing on a genetic disease may have options that do not alter inheritance. With IVF and preimplantation genetic diagnosis, embryos can be tested and disease-free embryos selected. Prenatal testing, donor eggs or sperm, embryo donation, adoption, and foster parenting are other possibilities, though they do not meet every family's preferences. For most couples at risk of Huntington's disease, embryo selection may avoid the condition.
A rare exception. If a parent has two faulty copies of a dominant disease gene, every child may inherit the condition, so selecting an unaffected embryo may not be possible. Advocates describe editing as a way to have a genetically related, healthy child. Baylis asks whether that preference constitutes a compelling medical need, especially when safer options exist and research resources are limited.
The strongest case for heritable editing is not abstract enhancement but the constrained family with no acceptable route to a genetically related child without disease. That case deserves attention without being inflated into a general necessity. The distinction between medical need and a deeply held preference is difficult because reproductive choices carry identity, cultural, and emotional weight. Still, calling a preference medical can hide the values driving it and can make alternatives seem less legitimate than they are. Ethical comparison requires taking both the desire and the alternatives seriously.
Distinguish embryo selection from DNA redesign, then judge the goal itself.
Choosing is not editing. IVF and preimplantation genetic diagnosis select among embryos; they do not rewrite DNA. Adam Nash, born after embryos were screened for both absence of Fanconi anemia and tissue compatibility with his ill sister, was widely called a designer baby. Yet his genes were selected, not modified. The process took four IVF cycles and involved 33 embryos. The label can obscure a meaningful difference between selection and genetic alteration.
The moral line is blurry. Editing for disease prevention and editing for athletic performance are often separated as treatment versus enhancement. Baylis argues that treatment also enhances a person by improving a condition, so the labels alone cannot settle the ethics. A better question is what the change is meant to do, how it affects others, and whether it worsens unfairness. The same genetic change can be judged differently in different social circumstances.
The distinction between selection and editing helps clear away a debate shaped by a catchy label. It also shows why moral categories need scrutiny: choosing an embryo with a preferred trait can have social consequences even without changing DNA, while an edit might aim to prevent severe suffering. Neither technology is ethically defined by its mechanism alone. At the same time, intention cannot carry the whole argument. A benign goal may still create harmful effects, and a socially accepted goal may reflect prejudice rather than a neutral idea of improvement.
Do not let genetic prevention turn human difference into a defect.
Genes are not destiny. Traits such as height and intelligence arise from interactions between genes and environments. Nutrition, education, health care, and social conditions matter too. Treating a trait as a simple genetic problem can misstate what an edit could achieve and distract from changes that help people without changing their biology.
Definitions shape lives. Some members of the Deaf community see efforts to eliminate hereditary deafness as a threat to a shared language and culture, not simply as disease prevention. Baylis also points to concerns about prenatal testing for conditions such as Down syndrome: widespread choices to avoid a condition may reinforce stigma and weaken support for people living with it. Preventing suffering can be a real good, but defining whose lives need correction is never purely technical.
The key ethical tension is between reducing an individual's burden and treating the trait as proof that the person is less welcome. Those aims are not identical. Respect for Deaf culture or disability communities need not deny the difficulties some individuals experience, just as offering treatment need not imply that all lives with a condition are inferior. A careful policy must preserve room for both personal choice and social accommodation. Otherwise, technology can make adaptation of society seem unnecessary precisely when affected people are losing voice and support.
Audit who bears the risks, pays the costs, and receives the cure.
Benefits may be exclusive. Research can be publicly funded while resulting therapies remain unaffordable. Baylis points to Glybera, a gene therapy priced at about one million US dollars. Only 31 people received it before it was withdrawn from the European market. Such examples challenge the promise that expensive innovations will naturally become accessible to everyone.
Research has human costs. Egg retrieval for embryo research can require hormonal stimulation and carries physical and psychological risks. In one study discussed in the book, healthy volunteers could receive up to $5,050, while fertility patients had no stated payment schedule. Baylis questions whether the consent process and payment arrangements treated participants fairly. Any assessment of genome editing must include not only the future patient, but also the women who provide eggs and the public that funds research.
This is a question of distribution, not merely a complaint that new medicine costs too much. Public investment, private ownership, participant risk, and patient access can be arranged so that different groups carry very different shares of the burden. The example of egg providers makes the same point within research itself: consent is not fair simply because a form is signed. A practical test for any proposed technology is to identify who has decision-making power, who absorbs uncertainty, and who can realistically benefit. Promises of future access are not a substitute for a plan.
A research framework can quietly turn "whether" into "how."
Policy shifted. In 2015, an international summit said reproductive use of germline editing would be irresponsible until safety questions were resolved and society broadly agreed that a proposed use was appropriate. In 2017, a US National Academies report described circumstances under which clinical trials might be permitted, including serious disease, no reasonable alternatives, and rigorous oversight. The emphasis shifted from whether society should proceed toward conditions for proceeding.
The consequences were visible. In 2018, researcher Jiankui He announced the birth of twins whose embryos had been edited in an attempt to reduce HIV susceptibility. The summit condemned the study for inadequate medical justification, poor design, ethical failures, and lack of transparency. In 2019, scientists called for a time-limited global moratorium. Baylis argues that policy language and scientific self-governance helped normalize a path before broad public agreement existed.
Rules do more than regulate conduct. They signal which questions are open and which have already been settled. A checklist for acceptable trials can appear cautious while implicitly treating eventual use as the destination. That can narrow public debate without an explicit decision to do so. A moratorium can create time to examine the destination, but it cannot by itself generate legitimacy or prevent secretive research. Its value depends on transparent enforcement, clear scope, and a process that includes people beyond scientific and policy elites.
Make science explain its choices, not quietly choose society's destination.
Speed has incentives. Baylis uses fast science for research shaped by competition, career rewards, and commercial interests. Slow science is the time and space to ask what research is for, consult affected people, and consider social consequences. It is not a rejection of discovery; it is a demand that the pace of research leave room for public reasoning.
Experts have different roles. A pure scientist produces knowledge. A science analyst explains evidence and uncertainty. An issue advocate argues for a preferred policy, while a science diplomat helps parties clarify options and find common ground. Baylis's related idea of Impact Ethics calls for bioethics that is innovative, responsible, and accountable. These roles make clear that expertise can inform a decision without automatically granting authority to make it.
The role distinctions are useful because appeals to scientific authority often blur explanation and advocacy. An expert can be transparent about values while still contributing essential technical knowledge. The strongest model is not a supposedly value-free expert, but a clearly situated one whose claims and interests can be examined. Slow science also asks institutions to change incentives, not just ask individual researchers to be more reflective. Without time, funding, and accountability for public relevance, deliberation risks becoming an unpaid extra attached to a system that rewards speed.
Give affected publics power to shape the rules, not just react.
Consultation is not control. Public education provides information; public engagement invites dialogue; public empowerment shares authority over the agenda and decisions. A meeting can appear participatory yet leave power with its organizers if they control the questions, materials, timing, and how public views are used.
Consensus takes work. Baylis discusses democratic deliberation, collective discernment, and consensus decision-making as ways to build shared understanding. Consensus does not require everyone to agree with every detail. It requires a fair hearing, respect for principled objections, and willingness to seek a workable common position. Because heritable editing could affect descendants and social relations across borders, she argues that decisions should involve scientists, patients, people with disabilities, policymakers, and the wider public, not only technical experts.
Public participation matters here because the dispute is not only about technical risk. It is also about which forms of human difference society values, who counts as a patient, and how much inequality is acceptable. A survey can record opinions but cannot show whether people understood the choices or influenced the decision. Consensus is also vulnerable to pressure: the desire for agreement can silence minorities unless dissent is protected. The soundest process treats consensus as a continuing practice of reason-giving and revision, not as a vote that ends disagreement.
Analysis
The book's central argument is not that human genome editing must be accepted or forbidden. It is that changing inheritance is a collective decision disguised, too easily, as a private medical choice. That distinction shifts the ethical focus from technical capability to authority: who defines a serious disease, who decides which futures count as improvements, and who bears the consequences when those decisions are wrong?
The case for editing is strongest when a severe genetic condition leaves prospective parents with no acceptable reproductive alternative. The emotional weight of that case should not be minimized. Yet moving directly from individual need to public permission risks mistaking a compelling story for a general policy. Alternatives, access, and the consequences for future children all matter. Conversely, concern about disability stigma cannot become a reason to dismiss the relief sought by people living with disease. The book is most persuasive when it keeps both truths visible.
Its sharpest contribution is to show that governance is not neutral plumbing around science. A committee's criteria, a report's vocabulary, or a meeting's agenda can quietly convert a disputed social choice into a technical question of implementation. This makes process substantive: transparency, representation, and power-sharing shape what can count as evidence and whose interests enter the decision.
Broad consensus is a demanding answer, not a magic one. Global agreement may be difficult, and insisting on consensus can delay work that could help people. But speed also distributes power, often toward those with money, institutional authority, and control over research. The relevant test is not whether debate slows discovery. It is whether the process makes a decision answerable to those whose bodies, descendants, and communities are at stake. The book asks readers to judge progress by that wider measure, rather than by the fact that a technique works.
Review Summary
Altered Inheritance receives mixed reviews, with ratings ranging from 2 to 5 stars. Readers appreciate the book's exploration of ethical issues surrounding genetic engineering and CRISPR technology. Some find it thought-provoking and essential for understanding the risks of altering the human genome. Critics note that parts of the book are dry and boring, with some chapters lacking depth. The author's call for public involvement in genetic editing discussions is praised, but her neutrality is questioned. Overall, reviewers recommend the book for its comprehensive coverage of the topic, despite its flaws.
People Also Read
Glossary
Somatic cell genome editing
Edits to nonreproductive cellsA genetic change made to a person's body cells rather than reproductive cells. The change may be made to cells outside the body and returned to the patient, or directly inside the body. It can potentially treat the person who receives it, but it is not passed to their children.
Heritable human genome editing
Edits passed to descendantsGenetic modification of reproductive cells or early embryos when the modified embryo is used to establish a pregnancy. The resulting changes can be inherited by the person's descendants. Unlike somatic editing, it is not simply a treatment for an existing patient; it deliberately changes what a family line can pass on.
Preimplantation genetic diagnosis
Testing embryos before transferA method used with in vitro fertilization to test cells from early embryos for particular genetic traits. Embryos with or without a specified condition can then be selected for transfer to a uterus. It selects among embryos rather than changing their DNA, and it can avoid passing on some genetic diseases when unaffected embryos are available.
Off-target effects
Edits at unintended DNA sitesUnwanted genetic changes made somewhere other than the intended DNA target. Such changes may disrupt genes or alter how cells function, potentially causing serious harm. They are one safety concern in genome editing, alongside harmful effects at the intended target and wider effects across genes, tissues, or chromosomes.
Mosaicism
Edited and unedited cells coexistA condition in which an organism that developed from one embryo contains different populations of cells. In genome editing, it can occur when some embryonic cells are successfully changed and others are not. This makes the final genetic outcome harder to predict and may mean that testing a sample misses changes elsewhere in the body.
Slow science
Science with time for reflectionAn approach that challenges research cultures organized around speed, competition, and rapid commercial payoff. It calls for time to think, investigate, consult, and deliberate about the purposes and consequences of research. It does not reject scientific progress; it argues that socially responsible science must consider its ends as well as its methods.
Fast science
Research driven by speed incentivesA pattern of research shaped by competition, career advancement, commercial interests, and pressure to produce results quickly. The concern is that speed can reward unreliable claims, narrow public debate, and prioritize marketable discoveries over the common good. In the book, fast science also describes efforts to focus debate on how to proceed rather than whether a technology should be pursued.
Broad societal consensus
Wide public agreement on useA process of international dialogue involving diverse communities, values, and expertise to assess whether a proposed use of heritable genome editing is appropriate. It requires more than scientific agreement or a public opinion poll. The aim is to build trust, hear divergent views, and develop a shared basis for decisions affecting descendants and society.
Impact Ethics
Accountable, policy-oriented bioethicsBaylis's term for a values-based approach to bioethics that seeks to influence policy while taking power, social conditions, and affected communities seriously. It emphasizes innovation, responsibility, and accountability. Its practitioners should clarify their commitments, attend to structural injustice, and create opportunities for people beyond professional elites to shape decisions.
Science diplomat
Expert who builds policy common groundA science expert who helps policymakers and publics understand the evidence behind different policy options, identify shared interests, and reach compromises without abandoning core values. Unlike an advocate, a science diplomat does not begin by narrowing debate to a preferred outcome. The role is to facilitate informed and integrity-preserving collective decisions.
Download PDF
Download EPUB
.epub digital book format is ideal for reading ebooks on phones, tablets, and e-readers.